0.6873 USD
0 (-0.16%)
0.6913 USD
+0 (+0.58%)
Taking everything into account, IMUX scores 2 out of 10 in our fundamental rating. IMUX was compared to 525 industry peers in the Biotechnology industry. The financial health of IMUX is average, but there are quite some concerns on its profitability. IMUX does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
- IMUX had negative earnings in the past year.
- IMUX had a negative operating cash flow in the past year.
- IMUX had negative earnings in each of the past 5 years.
- IMUX had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- Looking at the Return On Assets, with a value of -253.16%, IMUX is doing worse than 90.29% of the companies in the same industry.
- IMUX has a worse Return On Equity (-981.49%) than 79.24% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -253.16% | ||
| ROE | -981.49% | ||
| ROIC | N/A |
ROA(3y)-170.85%
ROA(5y)-121.12%
ROE(3y)-324.95%
ROE(5y)-215.14%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Profit Margin and Operating Margin and Gross Margin are not available for IMUX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- IMUX has more shares outstanding than it did 1 year ago.
- Compared to 5 years ago, IMUX has more shares outstanding
- IMUX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- IMUX has an Altman-Z score of -26.91. This is a bad value and indicates that IMUX is not financially healthy and even has some risk of bankruptcy.
- IMUX's Altman-Z score of -26.91 is on the low side compared to the rest of the industry. IMUX is outperformed by 85.71% of its industry peers.
- IMUX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -26.91 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
- A Current Ratio of 1.31 indicates that IMUX should not have too much problems paying its short term obligations.
- IMUX has a Current ratio of 1.31. This is amonst the worse of the industry: IMUX underperforms 82.48% of its industry peers.
- IMUX has a Quick Ratio of 1.31. This is a normal value and indicates that IMUX is financially healthy and should not expect problems in meeting its short term obligations.
- The Quick ratio of IMUX (1.31) is worse than 81.71% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.31 | ||
| Quick Ratio | 1.31 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 32.52% over the past year.
EPS 1Y (TTM)32.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.83%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
- The Earnings Per Share is expected to grow by 16.97% on average over the next years. This is quite good.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y36.69%
EPS Next 2Y27.48%
EPS Next 3Y15.44%
EPS Next 5Y16.97%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for IMUX. In the last year negative earnings were reported.
- Also next year IMUX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- IMUX's earnings are expected to grow with 15.44% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.48%
EPS Next 3Y15.44%
5. Dividend
5.1 Amount
- No dividends for IMUX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
IMMUNIC INC / IMUX FAQ
Can you provide the ChartMill fundamental rating for IMMUNIC INC?
ChartMill assigns a fundamental rating of 2 / 10 to IMUX.
Can you provide the valuation status for IMMUNIC INC?
ChartMill assigns a valuation rating of 0 / 10 to IMMUNIC INC (IMUX). This can be considered as Overvalued.
Can you provide the profitability details for IMMUNIC INC?
IMMUNIC INC (IMUX) has a profitability rating of 0 / 10.
What is the earnings growth outlook for IMMUNIC INC?
The Earnings per Share (EPS) of IMMUNIC INC (IMUX) is expected to grow by 36.69% in the next year.